Corporate Profile

The field of oncology is evolving rapidly and transforming how cancer is treated. We believe Incyte, rooted in rigorous science, is at the center of this transformation. Our pipeline includes innovative compounds in three major oncology areas: onco-inflammation, immuno-oncology and targeted therapies.

We believe our professional and financial resources, our experience and our prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders.

Recent News More >>
August 05, 2014FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 5, 2014-- Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The sNDA includes results from the RESPONSE Phase III trial, which were recently presen... 
Printer Friendly Version
July 31, 2014Incyte Reports 2014 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$84.0 million of 2014 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 55 percent growth over the same period last year 2014 guidance for Jakafi net product revenues increased to range of $330 million to $340 million, driven by strong underlying demand Timely initiation of key pipeline programs, including initiation of two pivotal trials of ruxolitinib in pancreatic cancer and three ... 
Printer Friendly Version
July 30, 2014Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies
Incyte’s investigational oral IDO1 inhibitor INCB24360 to be evaluated with Genentech’s investigational PD-L1 immune checkpoint inhibitor MPDL3280A WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 30, 2014-- Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibit... 
Printer Friendly Version

2013 Annual Report
2013 Annual Report Download Documentation

2013 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.